Rebecca Taub
2019
In 2019, Rebecca Taub earned a total compensation of $5.3M as President, Research & Development and Chief Medical Officer, at Synta Pharmaceuticals, a 21% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $274,775 |
|---|---|
| Option Awards | $4,531,120 |
| Salary | $463,948 |
| Total | $5,269,843 |
Taub received $4.5M in option awards, accounting for 86% of the total pay in 2019.
Taub also received $274.8K in non-equity incentive plan and $463.9K in salary.
Rankings
In 2019, Rebecca Taub's compensation ranked 2,049th out of 13,971 executives tracked by ExecPay. In other words, Taub earned more than 85.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,049 out of 13,971 | 85th |
Division Manufacturing | 745 out of 5,695 | 87th |
Major group Chemicals And Allied Products | 225 out of 2,194 | 90th |
Industry group Drugs | 182 out of 1,880 | 90th |
Industry Pharmaceutical Preparations | 132 out of 1,392 | 91st |
Pay ratio
| Rebecca Taub's Pay | $5,269,843 |
|---|---|
| Median Employee's Pay | $791,000 |
| Pay Ratio | 7to 1 |
In 2019, the annual total compensation of Rebecca Taub was $5,269,843.
The annual total compensation of the median employee at Synta Pharmaceuticals was $791,000.
The ratio of Rebecca Taub's pay to the pay of median employee was therefore 7 to one.
Source: SEC filing on April 29, 2020.
Taub's colleagues
We found four more compensation records of executives who worked with Rebecca Taub at Synta Pharmaceuticals in 2019.